Johnson & Johnson (NYSE:JNJ) Stock Holdings Lessened by LJI Wealth Management LLC

LJI Wealth Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,174 shares of the company’s stock after selling 199 shares during the period. LJI Wealth Management LLC’s holdings in Johnson & Johnson were worth $893,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. AMF Tjanstepension AB raised its position in Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after purchasing an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $209,000. Wealth Group Ltd. bought a new position in Johnson & Johnson during the third quarter worth about $213,000. Wedge Capital Management L L P NC increased its stake in Johnson & Johnson by 2.2% in the third quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock valued at $655,000 after purchasing an additional 86 shares in the last quarter. Finally, Creative Planning raised its stake in Johnson & Johnson by 4.3% during the 3rd quarter. Creative Planning now owns 988,403 shares of the company’s stock worth $160,181,000 after buying an additional 41,082 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Stifel Nicolaus decreased their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Finally, Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $155.23 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market cap of $373.73 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 2.46 and a beta of 0.52. The firm’s 50-day moving average is $147.48 and its 200 day moving average is $156.01. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.